Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking approach to diabetes management. These innovative drugs work by mimicking the inherent actions of GLP-1, a hormone produced by the gut in response to food. By activating GLP-1 receptors in the pancreas, these substances boost insulin release and reduce glucagon output

The burgeoning landscape of emerging treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting considerable weight decrease – they exhibit intriguing differences in t